Lumos Diagnostics’ industry workshop on advances in point-of-care diagnostics, drew big crowds at the American Association for Clinical Chemistry (AACC) Clinical Lab Expo.
Lumos CEO Dr Sacha Dopheide, Lumos R&D Director Jeff Bauer, and nanoComposix President and Founder Steve Oldenburg discussed ‘How Advances in Rapid Point-of-Care Technologies Are Enabling Ultra-High Sensitivity Detection of Biomarkers’.
Sacha spoke about how using readers could improve POC test sensitivity and also aid in assay development, while Steve discussed how advances in reporter particles and chemistry, particularly the development of gold nanoshells, was increasing the performance of lateral flow. Jeff used several real world case studies to demonstrate how these technological advancements were leading to the development of the next generation lateral flow rapid tests.
For those who could not make it to AACC, the workshop will be made available online as a webinar in the coming weeks.
Lumos Diagnostics Supports the Victorian Healthcare System by Providing FebriDx® for a Pilot Evaluation in the Triaging of Acute Respiratory Infection Patients
Lumos Diagnostics supports the Victorian healthcare system by providing FebriDx® for a pilot evaluation in the triaging of acute respiratory infection patients